0.6 mg to improve GI tolerability for at least 1 week1,a
Dosing and prescribing Victoza®

Consider a once-weekly GLP‑1 RA therapy for adult patients
Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.
How to start and maintain glycemic control for your Victoza® patients
Adult dosing instructions
1. Start

2. Maintain
1.2 mg for at least 1 week1

3. Titrate
1.8 mg for further glycemic control1

aThe starting dose of 0.6 mg is a nontherapeutic dose for adults.
How to write a prescription for adult patients in the e-prescribing system
Starting with Victoza®
0.6 mg
Victoza® (18 mg/3 mL)
Sig:
Inject 0.6 mg SC once daily for at least 7 days
Quantity:
6 mL (2-pen box)

Staying with Victoza®
1.2 mg
Victoza® (18 mg/3 mL)
Sig:
Inject 1.2 mg SC once daily for at least 7 days
Quantity:
6 mL (2-pen box)
1.8 mg
Victoza® (18 mg/3 mL)
Sig:
Inject 1.8 mg SC once daily
Quantity:
9 mL (3-pen box)

Pediatric (aged 10 and older) dosing instructions
1. Start and maintain
0.6 mg to improve GI tolerability for at least 1 week1

2. Titrate
1.2 mg if further glycemic control is needed1
If additional glycemic control is needed after at least 1 week of 1.2 mg dose, dose may be increased to 1.8 mg1

How to write a prescription for pediatric patients (≥10 years) in the e-prescribing system
Starting with Victoza®
0.6 mg
Victoza® (18 mg/3 mL)
Sig:
Inject 0.6 mg SC once daily for at least 7 days
Quantity:
6 mL (2-pen box)

If further glycemic control is needed
1.2 mg
Victoza® (18 mg/3 mL)
Sig:
Inject 1.2 mg SC once daily for at least 7 days
Quantity:
6 mL (2-pen box)

If further glycemic control is needed
1.8 mg
Victoza® (18 mg/3 mL)
Sig:
1.8 mg SC once daily
Quantity:
9 mL (3-pen box)


Victoza®
Instructions For Use
Step-by-step guidance on how to use the victoza® pen
Victoza® Instructions For Use
- There are no references associated with this video.